Scienmag

OCTOBER 15, 2020

LIN Wenchu from the High Magnetic Field Laboratory of the Hefei Institutes of Physical Science developed a synthesis of metal-free multifunctional therapeutic reagents, called graphitic carbon nitride quantum dots embedded in carbon nanosheets (CNQD-CN), via a one-step hydrothermal treatment. WANG Hui and Prof.

Reagent 85

Reagent Scientist Development Research 85

Drug Discovery World

NOVEMBER 2, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 26, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

FEBRUARY 6, 2023

CAS SciFinder is designed to provide solutions to challenges encountered in scientific research and discovery, across multiple stages of research and development, including reactions, synthesis, and relevant reference searching.

Reagent 52

Reagent Drugs Medicine Research 52

Drug Discovery World

OCTOBER 19, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Drug Discovery World

OCTOBER 12, 2023

You will hear from Fiona Elwood, VP, Disease Area Stronghold Lead, Neurodegeneration, Janssen, and Jenny Barnett, CEO of Monument TX, as well as Rosanna Zhang, Vice President of Corporate Development at ACROBiosystems. She will share examples of this precision medicine approach in cognitive impairment in schizophrenia and neuroinflammation.

Reagent 52

Reagent Drugs Development Medicine 52

Pharmaceutical Technology

SEPTEMBER 14, 2022

Victoza, Copaxone, Lupron, Zoladex, Sandostatin, and Somatuline are some of the popularly marketed peptide API therapeutic drugs while more than 600 peptide-based pharmacological leads are being investigated worldwide, across various phases of development. Technologies in the delivery of peptides and proteins.

Protein 130

Protein Marketing Manufacturing Reagent 130

The Pharma Data

MAY 17, 2021

Academic centers should establish risk management programs to successfully commercialize cell and gene therapy products and to be a viable partner with contract research organizations (CROs) and manufacturers in developing these therapies. . Uharek is a hematologist and cell and gene therapy specialist at Berlin’s Charité Hospital. .

Development 52

Development Gene Therapy Manufacturing Gene 52

Drug Discovery World

AUGUST 11, 2023

Research partners advance AAV gene therapy for heart disease Evox Therapeutics has agreed a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY, US. The post This week in drug discovery (7-11 August) appeared first on Drug Discovery World (DDW).

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Camargo

MAY 2, 2021

Advances in scientific knowledge and growth in the cell and gene therapy space have led to a new and exciting era of medicine for patients, as well as a new motivation for regulators to provide clear, efficient pathways for product developers. Note: Some medicines are in more than one category.

Gene Therapy 155

Gene Therapy Gene Packaging Packaging 155

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more.

Genome 244

Genome Genomics Medicine Gene Therapy 244

pharmaphorum

AUGUST 16, 2020

There are profound changes taking place in the area of life science research and development,” stated Swittons CEO and Founder Anupam Nandwana. Reorder reagents. Swittons is powered by the technology and expertise developed by P360. Notify of spill/cleaning needed. Equipment occupancy notification. Re-stock disposable supplies.

Life Science 130

Life Science Reagent Scientist Clinical Trials 130

The Pharma Data

JANUARY 24, 2021

a biotechnology company developing renewable stem cell-derived T cell therapies for cancer and other immune disorders, announced today the appointment of Chris Bond , Ph.D. Bond has extensive experience in the discovery and development of adoptive cell therapies, monoclonal antibodies, and cellular engineering and genome editing.

Engineer 52

Engineer Gene Editing Genome Genomics 52

Roots Analysis

FEBRUARY 21, 2022

Advancement in DNA sequencing technologies have resulted in noteworthy developments in various healthcare-related research fields, such as diagnostics and personalized medicine. Moreover, the manual protocols require extensive manipulation, costly reagents and long duration of skilled genomic library production.

Marketing 52

Marketing Gene Sequencing DNA Genome 52

Advarra

NOVEMBER 29, 2022

However, despite the promise of these therapies, the regulations governing them lag the science, which in turn hinders the clinical translation of these novel medicines. Recent Problems in Cell and Gene Therapy Development. The FDA recently announced a new initiative as part of its NIH Accelerating Medicines Partnership Program.

Gene Therapy 52

Gene Therapy Gene Production Clinical Trials 52

pharmaphorum

JANUARY 25, 2022

The Toronto-based company already counts many of the world’s largest pharma companies among its customers, using its platform for a range of tasks such as improving reagent and antibody selection to help scientists run more successful experiments, drawing on data from published studies and organisations’ internal databases.

Life Science 52

Life Science Pharma Companies Reagent Scientist 52

The Pharma Data

SEPTEMBER 8, 2021

TIB Molbiol excels in ultra-rapid assay development for emerging infectious disease, strongly demonstrated during the COVID-19 pandemic. For example, in 2001 with anthrax and 2003 with SARS-CoV1, TIB Molbiol demonstrated their ability to develop PCR assays for the detection of new pathogens within days. About TIB Molbiol.

Genotype 52

Genotype Reagent Genetics Research 52

Pharmaceutical Technology

FEBRUARY 15, 2023

The swift development and deployment of messenger-RNA (mRNA) vaccines against the SARS-CoV-2 virus during the COVID-19 crisis has catapulted the pharmaceuticals industry into a new paradigm. RNA has the potential to underpin breakthrough treatments for a wide variety of diseases, including many cancers, and transform medicine as we know it.

Bioassay 130

Bioassay Development RNA Drugs 130

The Pharma Data

MARCH 16, 2022

It’s critical to quickly and accurately identify variants to inform ongoing research – including the ongoing development of therapeutics and vaccines. We have developed a growing number of diagnostic solutions that help to detect and diagnose the infection, as well as providing digital support to healthcare systems.

In-Vitro 52

In-Vitro Genotype Reagent Protein 52

Drug Discovery World

APRIL 3, 2023

I quickly recognised the commercial value of aptamers as being able to address the gap in the market where antibodies fail to perform, and together we established the business to begin aptamer development. DS: How are aptamers currently used in the development of precision treatments? What advantages do they offer over antibodies?  

Antibody 52

Antibody Gene Therapy Gene In-Vitro 52

Drug Discovery World

MAY 16, 2023

Skills gap Bruce Levine, International Society for Cell & Gene Therapy (ISCT) Immediate Past President and Chair, Strategic Advisory Council, says a critical challenge that has become apparent for the CGT sector is the need for workforce development and training resources. The solution?

Gene Therapy 52

Gene Therapy Gene Manufacturing Marketing 52

The Pharma Data

MAY 15, 2023

The Sandoz Board of Directors will have 10 members in total and 3 sub-committees: a Science, Innovation & Development Committee, a Human Capital & ESG Committee and an Audit, Risk & Compliance Committee. She is also a board member at BBI Solutions, a UK based diagnostic reagents and a Novo Holdings company.

Sales 40

Sales Production Doctors Doctor 40

The Pharma Data

OCTOBER 19, 2020

DB ( Becton, Dickinson and Company ) received a CE mark for its BD Multitest 6-Color TBNK Reagent with BD Trucount Tubes for assessing immune function in COVID-19 patients. Army Medical Research and Development (USAMRDC ) initiated a Phase I clinical trial of its novel vaccine against COVID-19. Please read more here. .

Vaccination 52

Vaccination Vaccine Trials Clinical Trials 52

The Pharma Data

MARCH 13, 2021

“HAE is unpredictable, debilitating and potentially life-threatening, and recognition of the disease remains low in Japan, meaning there are significant challenges relating to diagnosis and access to effective therapies,” said Naoyoshi Hirota, General Manager, Takeda Development Center, Japan. Contraindication. Warnings and Precautions.

Drugs 52

Drugs Antibody Production Medicine 52

The Pharma Data

JULY 11, 2021

The efficacy of TAKHZYRO to prevent HAE attacks over the long term will be an important consideration for patients and physicians as they develop a treatment plan for patients that is focused on reducing the number of HAE attacks.”. Markus Magerl, M.D., Vice President, Global Medical Head, HAE and Transplant at Takeda. Contraindication.

Allergies 52

Allergies Antibody Recombinant DNA Technology Production 52

Drug Discovery World

DECEMBER 28, 2022

The Breath Biopsy VOC Atlas is a catalogue of validated and quantitated volatile organic compounds (VOCs) found on breath, designed to assist in the development of biomarkers and precision medicines. . Gyrolab Human Cytokine Kit Reagents are the first in a range of new biomarker kits from Gyros Protein Technologies. .

Production 97

Production Reagent Drugs Life Science 97

Drug Discovery World

DECEMBER 23, 2022

“We are pleased to partner with these prestigious biotechnology companies in advancing cell therapies for the betterment of those that are sick and in need,” said Michael, Head of GMP Business Development at GenScript.

Gene Therapy 52

Gene Therapy Gene Reagent Clinical Trials 52

Drug Discovery World

MARCH 13, 2023

Between the 24 therapies already approved by the FDA 1 and a marked increase in clinical trials, widespread accessibility to precision medicine feels within reach. Before 2019, CGT drug developers still had a young, academic mindset, ordering reagents, materials, and equipment haphazardly and assuming they would show up when needed.

Gene Therapy 52

Gene Therapy Gene Manufacturing Development 52

The Pharma Data

MARCH 20, 2021

The Challenge: The demands of many labs simultaneously beginning COVID-19 screening programs are leading to a scarcity of resources like pipette tips and reagents. Medicine in Oxford, Biogazelle, a biotechnology company in Ghent, and the Centre For Proteome Research at the University of Liverpool. delays where reagents are in.

Reagent 52

Reagent RNA Bioinformatics Medicine 52

Drug Discovery World

OCTOBER 21, 2022

Accordingly, advances in flow cytometry technology – both in instrumentation and reagent offerings – are enabling researchers to decipher these questions, leading to new discoveries and diagnostic tools. . Best antibody development practices are summarised in Fig. Overview, evolution, trends . Antibody titration .

Reagent 52

Reagent Antibody Drugs Protein 52

pharmaphorum

FEBRUARY 3, 2021

Dr Jennifer Harbottle, senior scientist in the R&D Base Editing team of PerkinElmer’s Horizon Discovery business, looks at progress made in the realms of biotechnology and next-generation diagnostics, vaccines and therapeutics, including the application of CRISPR-Cas9 gene editing in developing and refining cell therapies.

Gene Editing 98

Gene Editing Gene DNA Engineer 98

The Pharma Data

DECEMBER 2, 2020

Howard Mayer, Ipsen’s head of research and development, called the Fast Track designation for Onivyde “an extension of Ipsen’s focus and contribution” to the oncology landscape. The goal is to develop a first-in-class treatment for Staphylococcus aureus infections and thereby prevent exacerbation of pneumonia.

Drugs 52

Drugs Gene Editing Genome Genomics 52

FDA Law Blog

AUGUST 3, 2022

Mullen — Happy Birthday Laboratory Developed Tests (LDTs). In the LDT’s “toddler years,” when issuing its analyte specific reagent rule in 1997, FDA stated that it would generally exercise enforcement discretion over LDTS. As with any “child” they’ve matured and developed as they’ve grown into adulthood. By Jeffrey N.

In-Vitro 98

In-Vitro Regulation Compliance Production 98

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. Years of development and fast-paced research have continued to unlock its potential, expanding how CRISPR can be used to treat, detect, and prevent common diseases such as cancer and Covid-19.

DNA 98

DNA Genome Genomics RNA 98

FDA Law Blog

NOVEMBER 1, 2023

Gibbs — For more than three decades, FDA has claimed that the Federal Food, Drug & Cosmetic (FD&C Act) gives the agency legal authority to regulate laboratory developed tests (LDTs) as medical devices (see our prior post here ). The PR states that LDTs are not the “practice of medicine,” with which FDA generally may not interfere.

Regulation 81

Regulation In-Vitro Manufacturing Licensing 81

Drug Discovery World

JUNE 14, 2023

BCA members also operate the BCA Advanced Therapies Network which is a diverse, fully integrated portfolio of blood, cell, gene and tissue materials that support the development and delivery of advanced therapies. BCA and its members are developing innovative ways to attract younger donors through the use of technology.

Manufacturing 52

Manufacturing Production Gene Therapy Development 52

Drug Discovery World

FEBRUARY 15, 2023

Further discovery of PD-1 and CTLA4 as negative immune regulators led to the development of a new class of cancer therapeutics, namely the immune checkpoint inhibitors 5,6. Between 2017 and 2020, the number of IO therapies being developed has increased significantly from 2030 (for 265 targets) to 4,720 (for 504 targets).

Research 52

Research In-Vitro In-Vivo Development 52